Boston Scientific’s BSX fourth-quarter 2024 performance was driven by its robust expansion of operations across different geographies outside the United States. The company’s impressive strategic ...

The Watchman FLX Left Atrial Appendage Closure (LAAC) device represents a significant growth opportunity for Boston Scientific. The positive results from the OPTION clinical trial, demonstrating ...

Use of two high-risk cardiovascular devices—the Watchman (Boston Scientific) left atrial appendage occluder and the Impella (Abiomed) left ventricular assist device—is highest in the United States ...

The long-term prospects of the WATCHMAN devices are also encouraging. Meanwhile, headwinds like currency fluctuations pose a concern for Boston Scientific’s operations. In the past year ...

Boston Scientific’s product portfolio is a key driver of its success, with several standout offerings contributing to its strong market position. The Farapulse and Watchman products have shown ...

Boston Scientific’s product portfolio is a key driver of its success, with several standout offerings contributing to its strong market position. The Farapulse and Watchman products have shown ...